|Trade names||Crestabolic, Cytobolin, Diandren, Madiol, Stenediol, Mestenediol|
|Other names||Metandriol; Methylandrostenediol; Methylandrostenediole; 17α-Methylandrost-5-ene-3β,17β-diol|
|Drug class||Androgen; Anabolic steroid|
|Chemical and physical data|
|Molar mass||304.474 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Methandriol (INN) (brand names Crestabolic, Cytobolin, Diandren, Madiol, Stenediol, Mestenediol), also known as methylandrostenediol, as well as 17α-methylandrost-5-ene-3β,17β-diol, is a synthetic, orally active androgen and anabolic steroid (AAS) which was developed by Organon and is used in both oral and injectable (as methandriol dipropionate, methandriol propionate, or methandriol bisenanthoyl acetate) formulations. It is a 17α-alkylated AAS and the 17α-methylated derivative of the endogenous androgen prohormone androstenediol.
Methandriol has been used in the treatment of breast cancer in women.  It has been reported to be almost as virilizing as comparable doses of testosterone propionate and methyltestosterone in women.
|Fluoxymesterone||10–40 mg 3x/day|
|Calusterone||40 mg 4x/day|
|IM injection||Testosterone propionate||50–100 mg 3x/week|
|Testosterone enanthate||200–400 mg 1x/2–4 weeks|
|Testosterone cypionate||200–400 mg 1x/2–4 weeks|
|Methandriol (aq. susp.)||100 mg 3x/week|
|Androstanolone (aq. susp.)||300 mg 3x/week|
|Drostanolone propionate||100 mg 3x/week|
|Nandrolone decanoate||50–100 mg 1x/1–3 weeks|
|Nandrolone phenylpropionate||50–100 mg/week|
|Notes: Dosages are not necessarily equivalent. Sources: See template.|
Foss (1956), using methylandrostenediol in doses of 100 milligrams daily in the treatment of patients with inoperable carcinoma of the breast, found it almost as virilizing as testosterone propionate or methyltestosterone in comparable doses.
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|